gene therapy data and implications of aav9 antibodies
Published 5 years ago • 205 plays • Length 3:30Download video MP4
Download video MP3
Similar videos
-
2:58
prevalence of preexisting aav antibodies and implications for gene therapy in hemophilia
-
2:25
hemophilia aav gene therapy animation
-
20:57
overview of preexisting antibody testing prior to aav gene therapy presented by sarepta therapeutics
-
34:43
immunogenicity of aav vectors and transgenes - roland herzog
-
34:40
federico mingozzi: assessing and modulating immune responses to aav vectors in humans
-
38:38
global seroprevalence of pre-existing immunity against aav5 and other aav serotypes
-
2:23
current hurdles in aav-based gene therapy for hemophilia
-
19:49
automated parallel aav characterization with new tools for gene therapy
-
32:39
dmd and gene therapy what's on the horizon
-
6:01
aav integration summary and implications
-
36:32
gene therapy for fviii
-
4:14
utilising apheresis to remove neutralizing aav antibodies in patients previous excluded
-
18:36
reducing the immunogenicity of aav through engineering the vector - george church
-
1:57
aav gene therapies for hemophilia a and b
-
5:35
preexisting antibodies to aav and consequences for hemophilia gene therapy
-
2:25
enhancing aav gene therapy in children with inborn errors of metabolism
-
54:18
dave schaffer (10/3/2015) - evolving new synthetic viruses: sparking the gene therapy revolution
-
4:23
aav9-mediated gene therapy for cdkl5-deficiency disorder
-
4:15
synthetic aav vectors for gene therapy of hemophilia in children